Sarepta Therapeutics (SRPT) Earning Somewhat Positive Media Coverage, Report Shows

Press coverage about Sarepta Therapeutics (NASDAQ:SRPT) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sarepta Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.3606712096569 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

A number of research analysts recently issued reports on SRPT shares. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, December 25th. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, January 9th. JPMorgan Chase restated an “overweight” rating and set a $75.00 price target (up previously from $63.00) on shares of Sarepta Therapeutics in a research note on Wednesday, February 21st. Finally, Barclays restated a “hold” rating and set a $55.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, January 23rd. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $78.87.

Sarepta Therapeutics stock opened at $71.74 on Friday. Sarepta Therapeutics has a twelve month low of $28.14 and a twelve month high of $84.37. The company has a quick ratio of 12.96, a current ratio of 13.91 and a debt-to-equity ratio of 0.54. The company has a market cap of $4,734.32, a price-to-earnings ratio of -43.74 and a beta of 1.29.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The company had revenue of $57.30 million for the quarter, compared to analyst estimates of $57.33 million. During the same period in the previous year, the business posted ($0.71) earnings per share. The firm’s revenue was up 961.1% compared to the same quarter last year. research analysts forecast that Sarepta Therapeutics will post -1.18 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/sarepta-therapeutics-srpt-earning-somewhat-positive-media-coverage-report-shows.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply